AstraZeneca PLC (AZN) vs Johnson & Johnson (JNJ)
AstraZeneca PLC and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $652.8B against $257.8B — 2.5× the size. AstraZeneca PLC trades at the lower P/E: 24.7× against 31.4×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 8.06%. Johnson & Johnson has the higher net margin (21.5% vs 17.0%) and the higher return on invested capital (15.5% vs 11.7%). Both pay a dividend; Johnson & Johnson yields more (3.07% vs 2.49%). Across the 23 metrics below, Johnson & Johnson leads on 13 and AstraZeneca PLC on 10.
Valuation
Profitability
| Metric | AZN | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.88% | 67.91% | 72.77% |
| Operating margin | 22.77% | 27.69% | 18.90% |
| Net margin | 17.02% | 21.48% | 8.27% |
| Free cash flow margin | 10.21% | 23.20% | 17.25% |
| Return on equity | 21.95% | 25.74% | 6.97% |
| Return on assets | 9.15% | 10.67% | 2.76% |
| Return on invested capital | 11.67% | 15.51% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack